Background. Chemotherapy has become a standard of treatment in managing breast cancer. To achieve proper treatment for the right patients, the predictive marker is needed. Ki-67 is a biomarker of proliferation for solid tumor. Studies mentioned association of Ki-67 expression with chemotherapy response. The study aims are to evaluate whether Ki-67 expression detected by immunohistochemistry (IHC) and quantitative real-time polymerase chain reaction (qRT-PCR) may predict clinical response to neoadjuvant chemotherapy in breast cancer. Methods. This study utilized a longitudinal study. IHC and qRT-PCR methods were used for detection of Ki-67 expression. Chemotherapy response was calculated using RECIST. Data were analyzed with Chi-square and W...
Abstract Background The pathological complete response (pCR) after neoadjuvant chemotherapy is a sur...
In the neoadjuvant setting, changes in the proliferation marker Ki67 are associated with primary end...
BACKGROUND. The number of mitoses and, thus, the proliferative capacity of a tumor is one of the mos...
Background. Chemotherapy has become a standard of treatment in managing breast cancer. To achieve pr...
Background. Currently the choice of breast cancer therapy is based on prognostic factors. The prolif...
Background. Currently the choice of breast cancer therapy is based on prognostic factors. The prolif...
Background: Proliferation may predict response to neoadjuvant therapy of breast cancer and is common...
Increased proliferation activity of breast cancer cells evaluated by Ki-67 immunohistochemistry, i.e...
Several small studies have reported that having a high percentage of breast tumor cells that express...
To investigate the relationship between Ki67 expression and tumor response to neoadjuvant chemothera...
Journal International PrihantonoAbstract: Background: Proliferation is a distinct hallmarks of cance...
Systemic neoadjuvant chemotherapy (NCT) is a standard treatment for locally advanced breast cancer (...
Objective: To analyze the association of Ki-67 expression and response of neoadjuvant chemotherapy i...
Background: Ki-67 expression is strictly associated with cellular proliferation and is an excellent ...
Various clinicopathological factors are evaluated in different studies on carcinomas to demonstrate ...
Abstract Background The pathological complete response (pCR) after neoadjuvant chemotherapy is a sur...
In the neoadjuvant setting, changes in the proliferation marker Ki67 are associated with primary end...
BACKGROUND. The number of mitoses and, thus, the proliferative capacity of a tumor is one of the mos...
Background. Chemotherapy has become a standard of treatment in managing breast cancer. To achieve pr...
Background. Currently the choice of breast cancer therapy is based on prognostic factors. The prolif...
Background. Currently the choice of breast cancer therapy is based on prognostic factors. The prolif...
Background: Proliferation may predict response to neoadjuvant therapy of breast cancer and is common...
Increased proliferation activity of breast cancer cells evaluated by Ki-67 immunohistochemistry, i.e...
Several small studies have reported that having a high percentage of breast tumor cells that express...
To investigate the relationship between Ki67 expression and tumor response to neoadjuvant chemothera...
Journal International PrihantonoAbstract: Background: Proliferation is a distinct hallmarks of cance...
Systemic neoadjuvant chemotherapy (NCT) is a standard treatment for locally advanced breast cancer (...
Objective: To analyze the association of Ki-67 expression and response of neoadjuvant chemotherapy i...
Background: Ki-67 expression is strictly associated with cellular proliferation and is an excellent ...
Various clinicopathological factors are evaluated in different studies on carcinomas to demonstrate ...
Abstract Background The pathological complete response (pCR) after neoadjuvant chemotherapy is a sur...
In the neoadjuvant setting, changes in the proliferation marker Ki67 are associated with primary end...
BACKGROUND. The number of mitoses and, thus, the proliferative capacity of a tumor is one of the mos...